Royalty Report: Drugs, Disease – Collection: 239017


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239017

License Grant
Japanese Licensor grants an exclusive, running royalty-bearing license under the Patent Right and the Technical Information and Know-How to make, have made, import, offer to provide and provide, develop, manufacture, use, market, sell and offer to sell the Preparation in the Territory. License granted shall not include the right to grant sub-license in the Territory.
License Property
The patent is for a Locally administrable therapeutic composition for inflammatory disease.

The assets include U.S. product rights to bromfenac, a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammations and U.S. marketing rights for a new formulation of timolol, a beta-blocking agent for treating glaucoma.

Field of Use
The composition is for inflammatory disease and the patent has eye, nasal and otic applications.

IPSCIO Record ID: 239016

License Grant
Japanese Licensor shall transfer and assign any and all title and interest in the Governmental Approval to Licensee and shall grant Licensee an exclusive license to manufacture, import, market, promote, sell and distribute the Preparation under the Governmental Approval. Such license shall include exclusive right to use the Patent Right and Technical Information & Know-How to the extent that it is necessary for the sole purpose of manufacturing, importing, marketing, promoting, selling and distributing the ophthalmic product containing the Compound in the Territory.
License Property
The chemical compound is named timolol.  Timolol is a medication used either by mouth or as eye drops.

Preparation shall mean any ophthalmic product containing the Compound as an active ingredient, which is formulated and manufactured under the Patent Rights.

Field of Use
This agreement is for the sole purpose of manufacturing, importing, marketing, promoting, selling and distributing the ophthalmic product  an ophthalmic product for the treatment of glaucoma.

IPSCIO Record ID: 256228

License Grant
This Fourth Amendment amends the License Agreement between the Licensee and the Japanese Licensor, specifically establishes new lower royalty rates for the existing product until the proprietary new product is launched, and confirms the existing rate for the new product.
License Property
The products are PROLENSA™ and BROMDAY®.

PROLENSA™ and BROMDAY® medication used to treat swelling (inflammation) and pain in the eye after a certain type of eye surgery (cataract surgery). Bromfenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs).

Field of Use
The Licensee discovers, develops and markets new remedies for diseases and conditions of the eye.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.